Caty has over a decade of experience in market access consulting shaping value, access, policy, and pricing strategies across major European and global markets​.

She has worked across pharmaceuticals, vaccines, and medical devices including orphan and rare therapies, cell and gene therapies, and biologics and biosimilars.

In previous roles, including as Principal Consultant in the Market Access team at Evidera, she led a wide range of complex, multi-faceted project types across all stages of the product lifecycle, including HTA engagement and planning, value proposition development, pricing strategy and launch sequence planning, and in-licensing/due diligence assessments.

Caty obtained a MSc in International Health Policy from the London School of Economics and holds an undergraduate LLB degree in Law from the University of Exeter​.

‍

“I’m motivated by transforming clinical and economic evidence into clear value propositions and access pathways to help the right patients benefit from innovation sooner.”​

‍